Delving into the Latest Updates on GenPat77 Pharmacogenetics AG with Synapse

Overview

Basic Info

Introduction

GenPat77 Pharmacogenetics AG is a biotechnology company that specializes in the development of immune modulatory therapies for immune-mediated diseases. Established in 1998, the company is based in Berlin, Germany and has been dedicated to advancing the field of pharmacogenetics through its innovative research and development efforts.

Author: Bulwin, Grit-Carsta ; Schlawinsky, Mirko ; Bugge, Volker ; Blumberg, Richard S. ; Volk, Hans-Dieter ; Wiesner, Burkhard ; Lohan, Anke ; Winter, Michael ; Schulze, Anke ; Sabat, Robert ; Wälter, Stephanie ; Veh, Rüdiger W. ; Utku, Nalân ; Heinemann, Thomas ; Löhler, Jürgen ; Schülein, Ralf

AbstractAb targeting of TIRC7 has been shown previously to inhibit T cell proliferation and Th1 lymphocyte-associated cytokine production. In this study, we demonstrate that Ab targeting of TIRC7 induces early cell surface expression of CTLA-4. The majority of stimulated CD4+ and CD8+ human T cells coexpress CTLA-4 and TIRC7. Similar to CTLA-4, TIRC7 rapidly accumulates at the site of Ag adhesion upon T cell activation. TIRC7 seems to colocalize with CTLA-4 in human T cells, and both molecules are associated with clathrin-coated vesicles, indicating they share intracellular transport systems. Moreover, Ab targeting of TIRC7 results in an early activation of CTLA-4 transcription. The inhibition of cell proliferation mediated by TIRC7 is dependent on CTLA-4 expression because the TIRC7-mediated inhibitory effects on cell proliferation and cytokine expression are abolished by Ab blockade of CTLA-4. Splenocytes obtained from CTLA-4-deficient mice are not responsive to TIRC7 Ab targeting. Thus, TIRC7 acts as an upstream regulatory molecule of CTLA-4 expression.

16 Feb 2006·Clinical and Experimental ImmunologyQ3 · MEDICINE

Antibody targeting of TIRC7 results in significant therapeutic effects on collagen-induced arthritis in mice

Q3 · MEDICINE

Article

Author: Bulwin, C G ; Winter, M ; Nieuwenhuis, E E S ; Blumberg, R S ; Schlawinsky, M ; Fraser, P ; Volk, H-D ; Heinemann, T ; Utku, N

SummaryTIRC7 is a cell surface molecule which is expressed in T and B lymphocytes and negatively regulates their function. Anti-TIRC7 specific monoclonal antibody (mAb) inhibited T cell memory response to recall antigens. Up-regulation of TIRC7 on lymphocytes from joint tissue of patients with Rheumatoid Arthritis (RA) and mice with collagen induced arthritis (CIA) suggested TIRC7 as a novel target to promote anti-inflammatory reaction. Anti-TIRC7 mAb administration significantly inhibited the induction and progression of CIA and the anti-collagen IgG1 and IgG2a antibody response. Combination therapy of anti-TIRC7 mAb and soluble TNF-α receptor demonstrated an increased inhibitory effect over the single compounds on CIA. The results demonstrate the therapeutic potential of TIRC7 targeting with mAb in diseases associated with exaggerated T and B cell responses.

15 Aug 2004·The Journal of ImmunologyQ2 · MEDICINE

TIRC7 Deficiency Causes In Vitro and In Vivo Augmentation of T and B Cell Activation and Cytokine Response

Q2 · MEDICINE

Article

Author: Bennai-Sanfourche, Fatima ; Loehler, Jürgen ; Heinemann, Thomas ; Boerner, Anke ; Volk, Hans-Dieter ; Tomschegg, Antje ; Bulwin, Grit-Carsta ; Blumberg, Richard S. ; Utku, Nalân

AbstractThe membrane protein T cell immune response cDNA 7 (TIRC7) was recently identified and was shown to play an important role in T cell activation. To characterize the function of TIRC7 in more detail, we generated TIRC7-deficient mice by gene targeting. We observed disturbed T and B cell function both in vitro and in vivo in TIRC7−/− mice. Histologically, primary and secondary lymphoid organs showed a mixture of hypo-, hyper-, and dysplastic changes of multiple lymphohemopoietic compartments. T cells from TIRC7−/− mice exhibited significantly increased proliferation and expression of IL-2, IFN-γ, and IL-4 in response to different stimuli. Resting T cells from TIRC7−/− mice exhibited decreased CD62L, but increased CD11a and CD44 expression, suggesting an in vivo expansion of memory/effector T cells. Remarkably, activated T cells from TIRC7−/− mice expressed lower levels of CTLA-4 in comparison with wild-type cells. B cells from TIRC7-deficient mice exhibited significantly higher in vitro proliferation following stimulation with anti-CD40 Ab or LPS plus IL-4. B cell hyperreactivity was reflected in vivo by elevated serum levels of various Ig classes and higher CD86 expression on B cells. Furthermore, TIRC7 deficiency resulted in an augmented delayed-type hypersensitivity response that was also reflected in increased mononuclear infiltration in the skin obtained from TIRC7-deficient mice food pads. In summary, the data strongly support an important role for TIRC7 in regulating both T and B cell responses.

100 Deals associated with GenPat77 Pharmacogenetics AG

Login to view more data

100 Translational Medicine associated with GenPat77 Pharmacogenetics AG

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

5

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

GP-3.2 ( HLA class II antigen )	Infectious Diseases More	Pending
GP-2.2 ( CEACAM1 )	Inflammation More	Pending
GP-1.2 ( TCIRG1 )	Autoimmune Diseases More	Pending
GP-3.1 ( HLA class II antigen )	Inflammation More	Pending
GP-2.1 ( CEACAM1 )	Inflammation More	Pending